Advanced search
Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 7, 2022 - Issue 1
Submit an article Journal homepage
1,074
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma

Alessandro RizzoMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaCorrespondence[email protected]
View further author information
,
Angela Dalia RicciMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaView further author information
&
Giovanni BrandiMedical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaView further author information
Pages 1-3 | Received 30 Oct 2021, Accepted 15 Dec 2021, Published online: 27 Dec 2021

References

  • Finn RS, Qin S, Ikeda M, et al. IMbrave150 investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905. PMID: 32402160.
  • Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021 Jan 21;7(1):6. PMID: 33479224.
  • Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021 Jun;13(8):637–644. Epub 2021 Apr 6. PMID: 33820447
  • Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021 Sep 20;39(27):2991–3001. Epub 2021 Jul 22. PMID: 34292792; PMCID: PMC8445563.
  • Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 Apr 13;18:1–19. Epub ahead of print. PMID: 33850328; PMCID: PMC8042636.
  • Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019 Apr 11;380(15):1450–1462. PMID: 30970190.
  • Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2020 Oct 22. DOI:10.1001/jamaoncol.2020.3381. Epub ahead of print. PMID: 33090190.
  • Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017 Mar;66(3):545–551. Epub 2016 Nov 2. PMID: 27816492; PMCID: PMC5316490
  • Zhao M, Huang J, Lyu N, et al. Local thermal ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical progressive diseases during anti-PD-1 therapy. Ann Oncol. 2019;30:xi45.
  • Pinato DJ, Cole T, Bengsch B, et al. Phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL. Ann Oncol. 2019;30(Supplement_5):v288.
  • Ricke J, Klümpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019 Dec;71(6):1164–1174. Epub 2019 Aug 14. PMID: 31421157
  • Gebski V, Gibbs E, Gandhi M, et al. An individual patient data prospective meta-analysis of selective internal radiation therapy versus sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRveNIB trials. JMIR Res Protoc. 2017 Feb 15;6(2):e17. PMID: 28202430; PMCID: PMC5332836.
  • Tai D, Loke K, Gogna A, et al. A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678. J Clin Oncol. 2020;38(15_suppl):4590.
  • Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293–313. Epub 2021 Jan 28. PMID: 33510460.
  • Rizzo A, Dadduzio V, Ricci AD, et al., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2021 Jun 30:1–8. DOI:10.1080/13543784.2021.1948532. Epub ahead of print. PMID: 34167433.
  • Noonan A, Pawlik TM. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials. Expert Opin Investig Drugs. 2019 Nov;28(11):941–949. Epub 2019 Oct 12. PMID: 31590579
  • Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. Epub 2021 Feb 2. PMID: 33549983
  • Solimando AG, Susca N, Argentiero A, et al. Second-line treatments for advanced hepatocellular carcinoma: a systematic review and bayesian network meta-analysis. Clin Exp Med. 2021 Jun 19. DOI:10.1007/s10238-021-00727-7. Epub ahead of print. PMID: 34146196.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.